TX-MAVENIR
17.3.2022 14:03:02 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announces its complete Software as a Service (SaaS) based Business Communications portfolio, including customer engagement, business messaging, Communications Platform as a Service (CPaaS), Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS).
Mavenir leverages its global expertise in mobile networks, its relationships with hundreds of CSPs, enterprises and partners, and its leadership in the mobile messaging space to provide a Business Communications portfolio that enables omni-channel customer experiences to businesses of all sizes. The MAVbiz portfolio includes the following solutions:
> |
Mavenir Engage — Customer Engagement as a Service solution that combines multi-channel business messaging connectors (SMS, RCS, Apple Messages for Business, Google Business Messages) with business automations, chatbots, visual flow builder and campaign manager capabilities to enable conversational commerce capabilities for businesses of all sizes. |
||||
> |
Mavenir CPaaS — A full set of programmable APIs and turnkey applications (Smart 2FA, Number Masking, Call Routing) that allow businesses and developers to integrate communication capabilities into business processes and applications. |
||||
> |
Mavenir Connect — Unified Communication as a Service (UCaaS) solution that delivers a powerful set of high-definition voice, video, messaging, and meetings capabilities to allow workers to collaborate with colleagues and connect with customers anywhere, anytime and on any device. |
||||
> |
Mavenir Care — Contact Center as a Service (CCaaS) solution with omni-channel integrations, flexible and open APIs, business processes integrations (CRMs, AI platforms), visual IVR builder, and robust analytics and reporting. |
“Gartner predicts that 80% of customer service organizations will abandon mobile apps in favor of messaging by 2025i ," said Jorgen Nilsson, President, Enterprise Connect Business, Mavenir. “As a leader in messaging, with 60% SMS market shareii and over 3 billion mobile messaging subscribers globally, Mavenir is unlocking the power of business messaging to create a superior customer experience, leveraging our messaging footprint, certification as an Apple Messages for Business MSP and other key ecosystem partnerships.”
Mavenir’s Business Communications Solutions are designed to fit the needs of businesses of all sizes, micro, small and medium businesses to large enterprises, and are brought to market through CSPs, Channels or SIs, which can apply their own brand to the solutions and leverage Mavenir’s professional services, white-label marketing collateral, business operations and partner ecosystem relationships for fast time-to-market and subscriber growth.
Mavenir’s solutions deliver omni-channel interactions in every aspect of business communications and enable businesses with an affordable and fast enablement of their digital presence. By combining these solutions businesses can:
> |
Use Mavenir Engage chatbots and automations to offload repetitive tasks but leverage the human-in-the-loop (HITL) API to transfer messaging conversations to a representative using a Mavenir Care agent console |
||||
> |
Use Mavenir CPaaS APIs to send calls or text conversations from a business website or application to an employee using a Mavenir Connect endpoint. |
||||
> |
Transfer a customer call from the Mavenir Care agent console to another employee using a Mavenir Connect endpoint. |
||||
> |
Deflect incoming calls from the Mavenir Care contact center to a Mavenir Engage chatbot during busy hours or when the business is closed. |
Market dynamics are pointing towards omni-channel messaging in all aspects of business communication. 79% of consumers prefer live chats because they offer instant responsesiii and 53% of businesses saw an increase in workload due to the pandemiciv . Messaging increases productivity by allowing employees to handle multiple communications simultaneously.
Mavenir will be showcasing its Business Communications portfolio at Enterprise Connect 2022. Booth #1500 from March 21 to 24 in Orlando, Florida.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
| ______________________________ |
i Source: Gartner Newsroom |
ii Source: Mavenir based on GSMA Operator Subscribers |
iii Source: 99 Firms – Live Chat Statistics |
iv Source: User Testing – 2021 CX Industry Report |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005116/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom